FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 346:1346-1347 May 2, 2002 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lowes, B. D. PubMed Citation

According to current recommendations, -adrenergic–receptor blocking agents should be prescribed for all patients who have symptomatic heart failure and are in stable condition, unless these agents are contraindicated. The impetus for this approach is often traced to Göteborg, Sweden, where Waagstein and colleagues observed that the administration of -adrenergic–receptor blocking agents decreased pulmonary congestion in some patients with acute myocardial infarction and elevated heart rate. Speculating that "patients with congestive heart failure from other causes might also respond well to a reduction of tachycardia by beta-adrenergic receptor blockade," in 1975 they reported successful use of beta-blocking agents with partial intrinsic . . . [Full Text of this Article]

Who Are the Patients?

Which Beta-Blockers?

How to Titrate

This article has been cited by other articles:

• Priebe, H.-J. (2005). Perioperative myocardial infarction--aetiology and prevention. Br J Anaesth 95: 3-19 [Abstract] [Full Text]